Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Randomized controlled trials have investigated different first-line treatments for patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the long-term overall survival (OS) benefit in Asian patients with L858R mutation, remains unclear. METHODS: We per...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Sik-Kwan, Choi, Horace Cheuk-Wai, Lee, Victor Ho-Fun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065903/
https://www.ncbi.nlm.nih.gov/pubmed/35516725
http://dx.doi.org/10.1016/j.jtocrr.2022.100322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065903/
https://www.ncbi.nlm.nih.gov/pubmed/35516725
http://dx.doi.org/10.1016/j.jtocrr.2022.100322

Ejemplares similares